To The Moon

Forty-two U.S. stocks with market caps above $10 billion are trading at fresh all-time highs as of July 7, 2026. The top 10 span diversified banking, global consumer staples, power infrastructure, enterprise cybersecurity, class-I freight rail, and healthcare REITs—a pristine cross-section of the market's structural momentum right now.

The top 10 tickers leading this cohort - $Bank of America(BAC)$, $Coca-Cola(KO)$, $GE Vernova Inc.(GEV)$, $Palo Alto Networks(PANW)$, $CrowdStrike Holdings, Inc.(CRWD)$, $Union Pacific(UNP)$, $WELLTOWER OP LLC(WELL)$, $Vertex Pharmaceuticals(VRTX)$, $Fortinet(FTNT)$, $Bank of New York Mellon(BNY)$

🧭 Key Market Drivers

• AI-driven power infrastructure supercycle: Hyperscaler capex for AI data centers continues to reshape global power markets, with GEV the clearest beneficiary — gas turbine prices have risen roughly 300% over three years and its backlog now stands at a record $163 billion. UNP benefits indirectly as freight volumes and industrial capex tied to reindustrialization and data-center buildouts support record operating efficiency.

• AI-driven cybersecurity arms race: PANW, CRWD, and FTNT are all trading near records as enterprises rush to secure AI deployments against increasingly sophisticated, AI-assisted attacks. Wall Street has responded with a wave of triple-digit price-target hikes across the group, even as near-term margins absorb heavy M&A integration costs (PANW) and stock-based compensation (CRWD).

• Financials and staples riding resilient earnings into record territory: BAC and BNY both posted broad-based earnings beats this year on stronger trading, investment banking, and fee income, while KO continues to compound as a defensive, dividend-growing staple with accelerating organic sales. All three sit within fractions of a percent of their all-time highs.

• Healthcare compounders: growth and yield in one package: WELL is capturing outsized growth from the aging-in-place/senior-housing theme, with same-store NOI growth the highest in company history, while VRTX continues to diversify beyond cystic fibrosis into renal disease, sickle cell, and pain management, aided by a steady stream of regulatory wins.

1. $Bank of America(BAC)$

• Core Business: Diversified global bank operating through Consumer Banking, Global Wealth & Investment Management, Global Banking, and Global Markets segments.

• Latest Developments: Wells Fargo raised its price target to $67 from $65 on July 4, 2026. This followed Morgan Stanley's move to $67 from $61 on June 26, 2026, and JPMorgan's increase to $62.50 from $57.50. Oppenheimer, however, downgraded the stock to Perform from Outperform on June 30, 2026.

• Q1 2026 Financial Highlights: Revenue rose 7% to $30.4 billion, beating the $29.9 billion consensus; EPS of $1.11 beat the $1.01 estimate and marked the bank's highest EPS in nearly two decades. Net interest income grew 9% to $15.9 billion, prompting management to raise full-year NII guidance to 6-8% from 5-7%. Equities trading revenue jumped 30% to $2.83 billion, its best quarter in 15 years, while investment banking fees rose 21% to $1.8 billion.

• Price Target Outlook: Consensus rating is Strong Buy/Buy. Recent targets: Wells Fargo $67 (from $65), Morgan Stanley $67 (from $61), Truist $64 (from $61), JPMorgan $62.50 (from $57.50); Oppenheimer downgraded to Perform.

2. $Coca-Cola(KO)$

• Core Business: Nonalcoholic beverage manufacturer spanning sparkling soft drinks, water/sports/coffee/tea, and juice/dairy/plant-based categories globally.

• Latest Developments: On July 1, 2026, Coca-Cola announced a global agreement with Marriott International to expand its presence across Marriott's hotel portfolio. Separately, North America President Jennifer Mann will depart effective July 31, 2026, with CFO John Murphy assuming interim responsibility for the region starting August 1. Bernstein initiated coverage with a Market Perform rating and an $84 price target, while Morgan Stanley's Dara Mohsenian named Coca-Cola his Top Pick.

• Q1 2026 Financial Highlights: Adjusted EPS of $0.86 beat the $0.81 estimate; adjusted net revenue climbed 12% to $12.47 billion, with organic revenue up 10%. The company raised full-year guidance to organic revenue growth of 4-5% and comparable EPS growth of 8-9% (from 7-8%), citing a lower effective tax rate. Coca-Cola Zero Sugar volume rose 13% globally.

• Price Target Outlook: Buy consensus with an average target near $86-87. 24/7 Wall St. carries a $91.13 bull target implying roughly 8% upside.

3. $GE Vernova Inc.(GEV)$

• Core Business: Energy equipment and services company spanning Power (gas, nuclear, hydro, steam), Wind, and Electrification segments.

• Latest Developments: Q1 2026 orders surged 71% year-over-year to $18.3 billion, lifting backlog to a record $163 billion; management pulled forward its $200 billion 2027 backlog target by a year, citing AI data-center and electrification demand. Bernstein SocGen initiated coverage with an Outperform rating, and gas turbine pricing has risen roughly 300% over three years.

• Q1 2026 Financial Highlights: Revenue of $9.34 billion beat the $9.26 billion estimate; adjusted EPS came in between $1.98 and $2.06 versus consensus near $1.67-$1.90. Management raised full-year 2026 guidance to $44.5-$45.5 billion in revenue and $6.5-$7.5 billion in free cash flow, and authorized a $10 billion buyback while doubling the dividend.

• Price Target Outlook: Strong Buy consensus. Oppenheimer's Colin Rusch raised his target to $1,139 from $871; JPMorgan's Mark Strouse raised his to $1,150 from $1,000.

4. $Palo Alto Networks(PANW)$

• Core Business: Global cybersecurity provider spanning Network, Cloud, Security Operations, AI, and Identity platforms, serving over 70,000 customers.

• Latest Developments: The company closed its acquisition of Portkey, adding AI-gateway technology to its Prisma AIRS platform, and launched the Idira identity security platform. It also announced a NATO cyber-defense partnership alongside a Sovereign Cortex collaboration with Deutsche Telekom.

• Latest Earnings Highlights (Fiscal Q3 2026, ended April 30, 2026): Revenue of $3.00 billion beat the $2.94 billion estimate, up 31% year-over-year including $388 million from the CyberArk and Chronosphere acquisitions. Adjusted EPS of $0.85 beat the $0.80 estimate, though the company posted a GAAP net loss of $177 million on integration costs. Next-Gen Security ARR reached a record $8.13 billion, up 60%.

• Price Target Outlook: Strong Buy consensus. Wells Fargo's Michael Turrin raised his target to $355 from $165 on June 15, 2026; Citi's Fatima Boolani raised hers to $340 from $210; Goldman Sachs raised its target to $330 from $224.

5. $CrowdStrike Holdings, Inc.(CRWD)$

• Core Business: Cloud-delivered cybersecurity platform providing endpoint, cloud workload, identity, and data protection via a SaaS subscription model.

• Latest Developments: CrowdStrike completed a 4-for-1 stock split effective July 2, 2026. The company's pending ~$740 million acquisition of SGNL.AI, announced January 8, 2026, is expected to close in fiscal Q1 2027. Arete's Ellie Kearney downgraded shares to Neutral from Buy with a (pre-split) $730 price target.

• Latest Earnings Highlights (Fiscal Q1 2027, ended April 30, 2026): Revenue of $1.39 billion rose 26% year-over-year, ahead of estimates; adjusted EPS (pre-split) of $1.10 beat the $1.07 estimate. Net income was $27.8 million, reversing a year-ago net loss. Management raised fiscal 2027 net new ARR and revenue guidance, now expecting $5.915-$5.959 billion in full-year revenue.

• Price Target Outlook: Buy consensus, average target near $179 (post-split-adjusted, per 53 analysts). Views remain mixed given the stock's premium valuation.

6. $Union Pacific(UNP)$

• Core Business: Class I freight railroad transporting agricultural products, chemicals, energy, industrial goods, and intermodal containers across the western United States.

• Latest Developments: Shares surged 8.8% on April 23, 2026 following the Q1 report. Citi raised its price target to $307 from $285, and Raymond James raised its target to $310 from $285, both citing record efficiency metrics and CEO Jim Vena's operational focus. Evercore ISI raised its target to $294 from $277 on June 25, 2026.

• Q1 2026 Financial Highlights: Record operating revenue of $6.22 billion grew 3% year-over-year despite a 1% dip in volume, as freight revenue rose 4% on pricing and mix. Net income rose 5% to $1.7 billion with adjusted EPS of $2.93; the operating ratio improved to 60.5%, and freight car velocity hit a first-quarter record of 235 miles per day.

• Price Target Outlook: Moderate Buy/Strong Buy consensus with an average target near $293-296. Citi $307, Raymond James $310, Evercore ISI $294.

7. $WELLTOWER OP LLC(WELL)$

• Core Business: Healthcare REIT focused on senior housing, post-acute care, and health systems across the US, UK, and Canada.

• Latest Developments: Welltower raised its quarterly dividend 15% to $0.85 per share starting in the second quarter of 2026. BofA Securities raised its price target to $277 from $260 on May 26, 2026, while Scotiabank lowered its target to $232 from $248 on June 18, 2026, citing valuation.

• Q1 2026 Financial Highlights: Normalized FFO of $1.47 per share rose 23% year-over-year, with total portfolio same-store NOI growth of 16.4% — the highest in company history — driven by 22.1% same-store NOI growth in its senior housing operating portfolio. Full-year FFO guidance stands at $6.21-$6.35 per share.

• Price Target Outlook: Strong Buy consensus, average target roughly $238-244. BofA $277, Scotiabank $232.

8. $Vertex Pharmaceuticals(VRTX)$

• Core Business: Biotechnology company focused on cystic fibrosis (TRIKAFTA/KAFTRIO, ALYFTREK), sickle cell disease and beta thalassemia (CASGEVY), acute pain (JOURNAVX), and an emerging renal pipeline.

• Latest Developments: On July 1, 2026, the FDA expanded CASGEVY's approval to children aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia. Positive Phase 3 RAINIER interim data for povetacicept in IgA nephropathy showed a 52% reduction in proteinuria, supporting a BLA filing; the VX-522 mRNA program was discontinued due to tolerability issues.

• Q1 2026 Financial Highlights: Revenue of $2.99 billion rose 8% year-over-year but missed the $3.09 billion estimate; adjusted EPS of $4.47 beat the $4.31 estimate. Full-year guidance was maintained at $12.95-$13.1 billion in revenue, with ALYFTREK surpassing $1 billion in cumulative global sales.

• Price Target Outlook: Buy consensus. Morgan Stanley raised its target to $616 from $612; Barclays raised its target to $615 from $607; Truist initiated coverage at $542.

9. $Fortinet(FTNT)$

• Core Business: Cybersecurity provider offering next-generation firewalls, SASE, secure SD-WAN, and OT security solutions.

• Latest Developments: Fortinet disclosed a credential-harvesting campaign targeting its FortiGate firewalls and VPN devices. HSBC downgraded the stock to Reduce on June 30, 2026, even as BofA raised its price target to $180 from $130 and TD Cowen raised its target to $160 from $125 following management meetings.

• Q1 2026 Financial Highlights: Revenue of $1.85 billion rose 20% year-over-year, beating the $1.73 billion estimate, with billings up 31%. Adjusted EPS of $0.82 beat the $0.62 estimate. Management raised full-year 2026 revenue growth guidance to approximately 15%.

• Price Target Outlook: Rating: Buy (mixed sell-side views). BofA $180 (from $130); TD Cowen $160 (from $125); HSBC downgraded to Reduce on June 30, 2026.

10. $Bank of New York Mellon(BNY)$

• Core Business: The world's largest custody bank, providing securities services, market and wealth solutions, and investment management.

• Latest Developments: BNY changed its NYSE ticker from BK to BNY effective May 21, 2026, and announced a 19% dividend increase, from $0.53 to $0.63 per share, starting as early as the third quarter of 2026. The company also launched a digital mortgage collateral partnership with Snapdocs.

• Q1 2026 Financial Highlights: EPS came in at $2.24, with revenue growth of 13.8% topping analyst expectations by roughly 4.3%. The company repurchased 8.3 million shares for approximately $983 million during the quarter.

• Price Target Outlook: Strong Buy/Buy consensus, average target near $147-150. Goldman Sachs raised its target to $165 from $147; Truist raised its target to $160 from $148.